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Objective: To assess the impact of fingolimod (FTY720)
therapy on magnetic resonance imaging measures of in-
flammatory activity and tissue damage in patients par-
ticipating in a 2-year, placebo-controlled, phase 3 study.
Design: Patients with active relapsing-remitting multiple
sclerosis were randomized to receive fingolimod, 0.5 mg;
fingolimod, 1.25 mg; or placebo for 2 years. Standard-
ized magnetic resonance imaging scans were obtained at
months 0, 6, 12, and 24 and centrally evaluated for
number and volume of T1 gadolinium-enhancing, T2
hyperintense, and T1 hypointense lesions and for per-
centage of brain volume change. Findings were com-
pared across subgroups by treatment and baseline
characteristics.
Setting: Worldwide, multicenter clinical trial.
Patients: Patients were part of the fingolimod FTY720
Research Evaluating Effects of Daily Oral Therapy in Mul-
tiple Sclerosis (FREEDOMS) clinical trial for relapsing-
remitting multiple sclerosis (N=1272).
Main OutcomeMeasures: We measured the effect of
therapy on acute inflammatory activity, burden of dis-
ease, and irreversible loss of brain volume.
Results: Fingolimod therapy resulted in rapid and sus-
tained reductions in inflammatory lesion activity as as-
sessed by gadolinium-enhancing and new/newly en-
larged T2 lesions after 6, 12, and 24 months of therapy
(P .001, all comparisons vs placebo). Changes in T2 hy-
perintense and T1 hypointense lesion volume also sig-
nificantly favored fingolimod (P .05, all compari-
sons). Fingolimod, 0.5 mg (licensed dose), significantly
reduced brain volume loss during months 0 to 6, 0 to
12, 12 to 24, and 0 to 24 (P .05, all comparisons) vs
placebo, and subgroup analyses confirmed these effects
over 2 years irrespective of the presence/absence of gado-
linium-enhancing lesions, T2 lesion load, previous treat-
ment status, or level of disability.
Conclusion: These results, coupled with the signifi-
cant reductions in relapse rates and disability progres-
sion reported previously, support the positive impact on
long-term disease evolution.
Trial Registration: clinicaltrials.gov Identifier:
NCT00289978
Arch Neurol. 2012;69(10):1259-1269. Published online
July 2, 2012. doi:10.1001/archneurol.2012.1051
W ITH VARIOUS DISEASE-modifying thera-pies available to treatmultiple sclerosis(MS), research ef-
forts have turned toward finding effective
treatments that not only reduce inflamma-
tion but also target neurodegeneration. Fin-
golimod (FTY720, GILENYA; Novartis
Pharma AG) is the first in a new class of
therapeutic compounds called the sphin-
gosine 1–phosphate receptor (S1PR) modu-
lators that was recently approved at 0.5 mg
once daily for the treatment of relapsing MS.
Modulation of S1PRs on lymphocytesby fin-
golimod retains circulating lymphocytes in
the lymph nodes, thereby reducing the re-
circulation of autoreactive lymphocytes and
preventing their infiltration into the cen-
tral nervous system.1-4 In addition, preclini-
cal studies suggest that fingolimod limits
demyelination and restores the function of
neural cells.1-3,5 In an in vivo model,6 ex-
perimental autoimmune encephalomyeli-
tis progression in mice required the pres-
ence of S1PR subtype 1 (S1P1) on astrocytes.
Experimental autoimmune encephalomy-
elitis scores and spinal cord demyelination/
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neurodegeneration were strikingly reduced in mice lack-
ingastrocyticS1P1, suggestingabeneficial effectof functional
S1P1 antagonism in astrocytes, in addition to the known
peripheral anti-inflammatory effects of fingolimod.1
Inflammatory pathology in MS can be visualized by
counting gadolinium (Gd)-enhancing lesions on T1-
weighted images7 or new and enlarging T2 lesions on se-
rial magnetic resonance imaging (MRI) scans. These le-
sions represent areas of recent inflammation and correlate
with relapse rates in the short term.8 The extent of hy-
perintense areas on T2-weighted images provides an in-
dication of overall burden of disease (often referred to
as T2 burden of disease),9 although it lacks pathological
specificity because areas of hyperintensity can repre-
sent acute inflammation and edema or demyelination, glio-
sis, and permanent axonal loss.10
Neurodegenerative pathology in MS can be assessed
using other conventional MRI techniques: evaluation of
T1 hypointense lesions in T1-weighted images and mea-
sures of brain volume, including change in volume over
time. Chronic T1 hypointense lesions, also called “black
holes,” represent areas of severe demyelination, axonal
injury, and matrix destruction.10-13 Brain atrophy is the
consequence of permanent neuroaxonal loss (a key patho-
logical feature in MS progression) and can be observed
during the earliest stages of MS.14-16 It occurs at an ac-
celerated rate compared with healthy individuals and is
widely considered to be the main pathological substrate
of irreversible disability.7,15,17,18 Overall change in brain
volume is considered to be among the best studied and
most reliable in vivo measures of neurodegeneration, has
a significant correlation with physical disability, and seems
to be a stronger predictor of future disability than lesion-
based MRI measures.7,15,19 However, several factors must
be considered when interpreting changes in brain vol-
ume. Brain volume loss per se is not specific for neu-
roaxonal loss (ie, neurodegeneration). The early, acute
reductions in brain volume reported during the first few
months with established anti-inflammatory MS thera-
pies20-22 may represent a reduction in inflammation-
associated edema, a phenomenon described as pseudo-
atrophy.17,23 Reduction in the rate of brain volume loss
may therefore represent either an anti-inflammatory ef-
fect in the setting of inflammation and edema or an-
other mechanism independent of inflammation as yet un-
identified; such effects are not easily differentiated in
human studies.
Herein, we report the MRI results of a randomized,
placebo-controlled, phase 3 study of fingolimod in pa-
tients with relapsing-remitting MS, in which patients
treated with fingolimod had significant reductions in an-
nualized relapse rate and confirmed disability progres-
sion over 2 years, compared with placebo. The present
analysis evaluated the effect of therapy on acute inflam-
matory activity, burden of disease, and irreversible loss
of brain volume.
METHODS
FTY720 Research Evaluating Effects of Daily Oral Therapy in
Multiple Sclerosis (FREEDOMS) was a randomized, double-
blind, placebo-controlled, phase 3 trial involving 138 centers
in 22 countries from January 2006 to July 2009.24 It was con-
ducted in accordance with the International Conference on Har-
monization Guidelines for Good Clinical Practice25 and the Dec-
laration of Helsinki.26 An independent steering committee
Table 1. Baseline Demographic and Disease Characteristics of All 1272 Randomized Patients
Fingolimod, 1.25 mg
(n = 429)
Fingolimod, 0.5 mg
(n = 425)
Placebo
(n = 418)
Age, y
Mean (SD) 37.4 (8.9) 36.6 (8.8) 37.2 (8.6)
Median (range) 38.0 (17-55) 36.0 (18-55) 37.0 (18-55)
Female, No. (%) 295 (68.8) 296 (69.6) 298 (71.3)
White, No. (%) 408 (95.1) 406 (95.5) 399 (95.5)
EDSS score
Mean (SD) 2.4 (1.4) 2.3 (1.3) 2.5 (1.3)
Median (range) 2.0 (0-5.5) 2.0 (0-5.5) 2.0 (0-5.5)
Patients free from Gd-enhancing lesions, No. (%) 257 (60.6) 263 (62.0) 262 (63.0)
No. of Gd-enhancing lesions
Mean (SD) 1.8 (4.7) 1.6 (5.6) 1.3 (2.9)
Median (range) 0 (0-50) 0 (0-84) 0 (0-26)
Volume of Gd-enhancing lesions, mm3
Mean (SD) 197 (604) 170 (601) 162 (421)
Median (range) 0 (0-6853) 0 (0-6850) 0 (0-2970)
Volume of T2 lesions, mm3
Mean (SD) 6829 (8491) 6128 (7623) 6162 (7085)
Median (range) 3557 (0-47 734) 3303 (0-47 148) 3416 (0-37 148)
Volume of T1 hypointense lesions, mm3
Mean (SD) 2114 (3220) 1898 (2854) 1962 (3131)
Median (range) 860 (0-25 886) 814 (0-22 378) 811 (0-20 956)
Normalized brain volume, cm3
Mean (SD) 1511 (86) 1521 (83) 1512 (85)
Median (range) 1515 (1217-1764) 1529 (1144-1734) 1515 (1230-1723)
Abbreviations: EDSS, Expanded Disability Status Scale; Gd, gadolinium.
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consisting of academic investigators collaborated with the spon-
sor (Novartis Pharma AG) to design the study and monitor its
conduct. The protocol was approved by the institutional re-
view board at each site and all patients gave written informed
consent before any study-related procedures were performed.
PATIENTS
The study design and inclusion/exclusion criteria have been pub-
lished previously,24 in accordance with the CONSORT guide-
lines. Briefly, patients were randomly assigned (1:1:1 ratio) to
once-daily fingolimod capsules, 0.5 mg or 1.25 mg, or match-
ing placebo for 24 months.24 Patients had to be aged 18 to 55
years with a diagnosis of MS according to the revised McDonald
criteria,27 a relapsing-remitting course, 1 or more documented
relapses in the previous year (or 2 or more in the previous 2
years), and a score of 0 to 5.5 on the Expanded Disability Sta-
tus Scale (EDSS).28 Key exclusion criteria were relapse or cor-
ticosteroid treatment within 30 days before randomization, ac-
tive infection, drug- or disease-induced immune suppression,
or clinically significant systemic disease. Interferon beta or glati-
ramer acetate therapy had to have been stopped 3 months or
more before randomization. Other previous therapies had to
have been discontinued for 6 months or more before random-
ization. Patients were also excluded if they were unable to un-
dergo MRI scans, including those with claustrophobia or a his-
tory of severe hypersensitivity to Gd–diethylenetriamine
pentaacetic acid.
MRI PROCEDURES
Standardized MRI scans were obtained at screening and at 6,
12, and 24 months and were analyzed centrally at the Medical
Image Analysis Center at the University Hospital in Basel, Swit-
zerland. The central reader checked scans for completeness and
quality, after which all scans were analyzed by trained techni-
cians and reviewed by radiologists, all of whom were unaware
of study-group assignments. Details of MRI assessments are pro-
vided in the eAppendix (http://www.archneurol.com).
At each study visit, T1-weighted images, before and after
administration of contrast medium (single dose of 0.1 mmol/kg
intravenously), and T2-weighted images (T2 and proton den-
sity) were obtained according to a standardized imaging pro-
tocol (eTable) at certified sites. Investigators were requested
to avoid carrying out MRI scans within 30 days of initiation of
steroid treatment.
Lesions were identified and marked by radiologists or spe-
cially trained personnel on the digital images following a stan-
dardized operating procedure. In case of doubt, lesions were
discussed in consensus reading sessions. Once lesions were iden-
tified, volume calculations were performed by other specially
trained technicians (mean intratechnician variability of 3.02%
within the MS MRI team at the Medical Image Analysis Cen-
ter) using an interactive segmentation program developed on
the Amira platform (Mercury Computer Systems GmbH). Af-
ter lesions were marked and segmented, these processes were
reviewed and approved by a radiologist.
Percentage of brain volume change (PBVC) between base-
line and each postbaseline scan was calculated using the SIENA
software included in the Functional Magnetic Resonance Imaging
of the Brain software library (FMRIB Analysis Group, Oxford
University). At baseline, the single-point SIENA cross-
sectional counterpart, SIENAX, was used to estimate the nor-
malized brain volume.
STATISTICAL ANALYSES
All efficacy analyses, including MRI analyses (all prospectively
defined secondary end points), were evaluated in the intent-to-
treat population, which comprised all randomized patients. Ad-
ditionally, patients needed to have evaluable MRI scans to be in-
cluded in the MRI analyses. All between-group differences were
Table 2. Inflammatory Lesion Activity on Magnetic
Resonance Imaging as Assessed by New/Newly Enlarged T2
and Gd-Enhancing Lesions (Intent-to-Treat Population)
Fingolimod,
1.25 mg
(n = 429)
Fingolimod,
0.5 mg
(n = 425)
Placebo
(n = 418)
No. of New/Newly Enlarged T2 Lesions
Months 0-6
Patients with data, No. 392 408 394
Mean (SD) 1.1 (2.5) 1.0 (2.6) 3.6 (7.9)
Median (range) 0 (0-27) 0 (0-28) 1.0 (0-96)
P value vs placeboa .001 .001 . . .
Months 0-12
Patients with data, No. 378 401 367
Mean (SD) 1.5 (3.2) 1.6 (4.5) 5.5 (8.0)
Median (range) 0 (0-28) 0 (0-63) 3 (0-78)
P value vs placeboa .001 .001 . . .
Months 13-24
Patients with data, No. 338 371 340
Mean (SD) 1.1 (3.6) 0.9 (3.3) 4.3 (7.9)
Median (range) 0 (0-32) 0 (0-44) 2 (0-69)
P value vs placeboa .001 .001 . . .
Months 0-24
Patients with data, No. 337b 370b 339b
Mean (SD) 2.5 (5.5) 2.5 (7.2) 9.8 (13.2)
Median (range) 0 (0-41) 0 (0-107) 5 (0-99)
P value vs placeboa .001 .001 . . .
Gd-Enhancing Lesion Outcomes
Gd-enhancing lesion count
Month 6
Patients with data, No. 388 403 373
Mean (SD) 0.3 (1.1) 0.2 (0.8) 1.3 (3.4)
Median (range) 0 (0-12) 0 (0-13) 0 (0-43)
P value vs placebob .001 .001 . . .
Month 12
Patients with data, No. 376 394 356
Mean (SD) 0.3 (1.0) 0.2 (1.4) 1.1 (2.2)
Median (range) 0 (0-11) 0 (0-21) 0 (0-19)
P value vs placebob .001 .001 . . .
Month 24
Patients with data, No. 343 369 332
Mean (SD) 0.2 (1.1) 0.2 (0.8) 1.1 (2.4)
Median (range) 0 (0-11) 0 (0-8) 0 (0-21)
P value vs placebob .001 .001 . . .
Volume of Gd-enhancing
lesions, mm3
Month 6
Patients with data, No. 388 403 373
Mean (SD) 35 (151) 26 (153) 142 (415)
Median (range) 0 (0-1545) 0 (0-2538) 0 (0-5233)
P value vs placeboa .001 .001 . . .
Month 12
Patients with data, No. 376 394 356
Mean (SD) 46 (246) 39 (276) 135 (340)
Median (range) 0 (0-3511) 0 (0-5070) 0 (0-2215)
P value vs placeboa .001 .001 . . .
Month 24
Patients with data, No. 343 369 332
Mean (SD) 29 (152) 39 (245) 149 (439)
Median (range) 0 (0-1940) 0 (0-3943) 0 (0-4395)
P value vs placeboa .001 .001 . . .
Abbreviations: ellipses, not applicable; Gd, gadolinium.
aNegative binomial model adjusted for treatment and country.
b Includes patients who had completed to month 24 and had a follow-up
visit thereafter.
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assessed in a pairwise manner and missing data were not im-
puted. Between-group differences in the numbers of new/newly
enlarged T2 lesions were assessed using a negative binomial model
adjusted for treatment and country. Rank analysis of covari-
ance adjusted for treatment, country, and baseline number or
volume of Gd-enhancing lesions was used to assess between-
group differences in the number or volume of Gd-enhancing le-
sions, respectively. The proportions of patients who were free
from Gd-enhancing T1 lesions or new inflammatory activity (Gd-
enhancing lesions and new/newly enlarged T2 lesions) were ana-
lyzed using a logistic regression model adjusted for treatment,
country, and baseline number of Gd-enhancing T1 lesions. The
proportions of patients who were free from new/newly en-
larged T2 lesions were analyzed using a logistic regression model
adjusted for treatment and country (no baseline T2 counts were
performed). Absolute and percentage of changes from baseline
in the total volume of T2 lesions or T1 hypointense lesions were
assessed by rank analysis of covariance adjusted for treatment,
country, and corresponding baseline lesion volume (T2 or T1
hypointense volume, respectively). Between-group differences
in PBVC were assessed using rank analysis of covariance ad-
justed for treatment, baseline normalized brain volume, and re-
gion. Post hoc subgroup analyses were performed to assess PBVC
according to baseline treatment status (treatment-naive or pre-
viously treated), EDSS score (0-3.5 points or3.5 points), Gd-
enhancing lesion status (present or absent), or T2 lesion vol-
Table 3. Magnetic Resonance Imaging Outcomes for Volume of T2 Lesions and T1 Hypointense Lesions (Intent-to-Treat Population)a
Fingolimod,
1.25 mg
(n = 429)
Fingolimod,
0.5 mg
(n = 425)
Placebo
(n = 418)
T2 Lesion Load
Absolute change in T2 lesion
volume from baseline to month
12, mm3
Patients with data, No. 375 401 365
Mean (SD) −108 (1856) −153 (1972) 526 (1559)
Median (range) −40 (−12 850 to 17 282) −20 (−26 046 to 17 628) 152 (−7119 to 10 775)
P value vs placebob .001 .001 . . .
Absolute change in T2 lesion
volume from baseline to month
24, mm3
Patients with data, No. 345 372 342
Mean (SD) −96 (2167) −24 (2360) 1045 (2716)
Median (range) −60 (−15 253 to 17 508) −42 (−27 657 to 22 893) 357 (−5142 to 33 170)
P value vs placebo .001 .001 . . .
Percentage of change in T2 lesion
volume from baseline to month
12, mm3
Patients with data, No. 373 397 361
Mean (SD) 2.7 (38.1) 3.4 (35.2) 18.7 (80.5)
Median (range) −2.2 (−71 to 381) −0.8 (−100 to 279) 3.9 (−62 to 1098)
P value vs placebob .001 .001 . . .
Percentage of change in T2 lesion
volume from baseline to month
24, mm3
Patients with data, No. 343 368 339
Mean (SD) 1.6 (30.7) 10.6 (103.5) 33.8 (106.9)
Median (range) −3.1 (−68 to 221) −1.7 (−100 to 1829) 8.6 (−85 to 1379)
P value vs placebo .001 .001 . . .
T1 Hypointense Lesion Load
Absolute change in T1
hypointense lesion volume
from baseline to month 24,
mm3
Patients with data, No. 343 372 340
Mean (SD) 30 (674) 33 (536) 173 (690)
Median (range) 0 (−2403 to 7811) 0 (−4913 to 3462) 2.9 (−3440 to 5857)
P value vs placebo .001 .008 . . .
Percentage of change in T1
hypointense lesion volume
from baseline to month 24,
mm3
Patients with data, No. 317 346 305
Mean (SD) 12.2 (85.5) 8.8 (76.3) 50.7 (388.3)
Median (range) −0.2 (−100 to 888) 0.0 (−100 to 1037) 1.6 (−100 to 5285)
P value vs placebo .02 .01 . . .
Abbreviation: ellipses, not applicable.
aP values calculated using rank analysis of covariance adjusted for treatment, country, and volume of corresponding lesions at baseline.
bP values based on descriptive statistics.
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ume (3300 mm3 or3300 mm3); details of these analyses are
provided in the eAppendix. No adjustment for multiple analy-
ses was performed for the secondary or post hoc analyses.
RESULTS
STUDY POPULATION
Baseline patient demographics and MRI characteristics
were broadly similar across treatment groups (Table 1);
although baseline MRI parameters for the fingolimod, 1.25
mg, group were slightly worse than fingolimod, 0.5 mg,
and placebo, these differences were not clinically mean-
ingful. In total, 1033 of 1272 patients (81.2%) com-
pleted the 24-month study, with 945 individuals (74.3%)
still receiving the assigned study drug.24 The number of
evaluable MRI scans at baseline and months 6, 12, and
24 are reported in Tables 1, 2, and 3 for each of the
assessed MRI outcomes. Across treatment groups, evalu-
able MRI scans and brain volume data were available in
98.6% to 99.8% of patients at baseline, 89.2% to 96.0%
at month 6, 85.2% to 94.4% at month 12, and 77.9% to
87.5% of individuals at month 24. Reasons for missing
scans were not collected. As stated in the “Methods” sec-
tion, no adjustment was made for multiple analyses.
INFLAMMATORY LESION ACTIVITY
Both fingolimod doses reduced the number of new/
newly enlarged T2 lesions over 24 months compared with
placebo (P  .001); the reductions were significant by
month 6 and remained so during the 24-month study
(P  .001 for all comparisons of fingolimod vs placebo)
(Table 2). Patients treated with either dose of fingoli-
mod also had fewer Gd-enhancing lesions and lower Gd-
enhancing lesion volumes at each postbaseline MRI as-
sessment than patients treated with placebo (P  .001
for all comparisons).
More patients receiving fingolimod than those receiv-
ing placebo were free from new/newly enlarged T2 le-
sions, Gd-enhancing lesions, or both (ie, free of new in-
flammatory activity) at all assessments throughout the
study (P  .001) (Figure 1).
T2 BURDEN OF DISEASE
Burden of disease evolution, as assessed by change in T2
lesion volume, was lower in patients treated with either dose
of fingolimod over 24 months than with placebo (P .001
for all comparisons) (Table 3). Absolute T2 lesion volume
decreased slightly from baseline to months 12 or 24 in both
fingolimod groups and increased in the placebo group.
T1 HYPOINTENSE LESION VOLUME
Total T1 hypointense lesion volume remained stable dur-
ing months 0 to 24 in patients receiving fingolimod, while
a slight increase was observed in the placebo group. The
difference in change from baseline to month 24 favored
both doses of fingolimod over placebo (P  .05 for all
comparisons) (Table 3).
BRAIN VOLUME CHANGE
As reported previously,24 both fingolimod doses re-
duced mean PBVC during months 0 to 24 compared with
placebo in the overall study population (P  .001). This
reduction in PBVC was significant by month 6 and was
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Figure 1. New or inflammatory lesion activity over time. Lesions were
assessed by the proportions of patients free from gadolinium
(Gd)-enhancing lesions (A), new or enlarging T2 lesions (B), and both
Gd-enhancing and new/newly enlarged T2 lesions (intent-to-treat population)
(C). Data are percentage (number of patients with evaluable magnetic
resonance imaging [MRI] scans) of patients free from lesions in the
intent-to-treat population and 95% confidence intervals are based on the
binomial distribution using equal-tailed tests. In part A, P values were
determined using a logistic regression model adjusted for treatment,
country, and baseline Gd-enhancing lesion count. In part B, P values were
determined using a logistic regression model adjusted for treatment and
country. In part C, P values were determined using a logistic regression
model adjusted for treatment, country, and baseline Gd-enhancing lesion
count.
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sustained during months 0 to 12 and 12 to 24 (P  .05
for both doses at all 3 intervals) (Figure 2A). The rela-
tive reduction in brain volume loss for fingolimod, rela-
tive to placebo, ranged from 23% to 45% at the various
intervals.
To evaluate the influence of the anti-inflammatory ef-
fect of fingolimod on brain volume change, the results
were stratified according to whether patients had Gd-
enhancing lesions at baseline. The first finding of note
is that brain volume declined approximately twice as
quickly in patients with Gd-enhancing lesions at base-
line as in those without Gd-enhancing lesions in both the
placebo and fingolimod groups. Second, irrespective of
baseline Gd-enhancing lesion activity, both fingolimod
doses significantly reduced brain volume loss over 2 years
compared with placebo (Figure 2B and C). Finally, the
temporal evolution of brain volume loss differed be-
tween patients with Gd-enhancing lesions at baseline and
those without (Figure 2B and C). For individuals with
active inflammation at baseline (Gd-enhancing lesions
present), brain volume in the placebo group decreased
steadily throughout the study and at a faster rate than in
those without Gd-enhancing lesion activity. In patients
receiving fingolimod, brain volume loss occurred at a simi-
lar rate to placebo during the first 6 months, slowed
slightly during the second 6 months, and then was con-
siderably slower than placebo during the second year. For
patients without Gd-enhancing lesions at baseline, brain
volume again decreased steadily in those receiving pla-
cebo. In contrast, with fingolimod therapy, there was an
immediate reduction in the rate of brain volume loss com-
pared with placebo, which was greatest during the first
6 months and relatively steady thereafter but pro-
gressed more slowly than placebo. No significant differ-
ences in the magnitude of the effect between the 2 fin-
golimod doses were noted (P  .10 for subgroup
interactions). At no point did the rate of brain volume
loss in fingolimod-treated patients exceed that in the pla-
cebo group, irrespective of baseline MRI activity.
Other subgroup analyses (Table 4) assessing PBVC
during months 0 to 24 indicated that both fingolimod
doses were superior to placebo irrespective of T2 lesion
volume at baseline (3300 mm3 or3300 mm3) and that
fingolimod, 0.5 mg, was superior to placebo regardless
of whether patients had received disease-modifying
therapy for MS; the difference approached significance
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Figure 2. Mean percentage of brain volume change (PBVC) from baseline in the overall study population (A) and in patients with (B) or without (C) gadolinium
(Gd)-enhancing lesions at baseline.
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for fingolimod, 1.25 mg, in previously treated patients.
Brain volume loss was also significantly reduced by both
fingolimod doses in individuals with EDSS scores of 0
to 3.5; although a similar numerical difference was ob-
served in those with scores more than 3.5 (P = .50 for
subgroup interaction between patients with lower and
higher EDSS scores), the difference did not reach sig-
nificance compared with placebo in this smaller sub-
group. Patients with higher EDSS scores and larger T2
volumes at baseline had greater degrees of brain volume
loss than their complementary group (both placebo and
fingolimod groups). There was relatively little differ-
ence in the extent of brain volume loss between groups
when segregated by previous therapy status.
Overall, the magnitude of PBVC, relative to placebo,
ranged from 24% to 49% for the various subgroups,
with the greatest relative changes seen in the previously
treated fingolimod, 0.5 mg, group and the smallest rela-
tive effect in the treatment-naive fingolimod, 0.5 mg,
group. However, effect size was reversed in these same
subgroups for the fingolimod, 1.25 mg, group.
COMMENT
These analyses from the 2-year FREEDOMS study con-
firm that the efficacy of fingolimod therapy is robust across
all MRI end points. The anti-inflammatory effects of fin-
golimod therapy, as depicted by Gd-enhancing lesions
and new/newly enlarged T2 lesions, were evident as early
as 6 months after treatment initiation and were sus-
tained over 2 years. Approximately half the patients re-
ceiving fingolimod therapy were free from any new in-
flammatory lesions throughout this 2-year study,
Table 4. Magnetic Resonance Imaging Outcomes for Percentage of Change in Brain Volume During Months 0 to 24 by Patient
Subgroup (Intent-to-Treat Population)a
Fingolimod, 1.25 mg
(n = 429)
Fingolimod, 0.5 mg
(n = 425)
Placebo
(n = 418)
T2 lesion volume 3300 mm3
No. of patientsb (c) 201 (156) 212 (185) 206 (169)
Mean (SD) −0.40 (1.15) −0.47 (0.92) −0.75 (0.96)
Median (range) −0.41 (−5.2 to 3.0) −0.44 (−3.5 to 2.2) −0.65 (−4.0 to 2.4)
P value vs placebod .001 .02 . . .
Percentage of relative reduction vs placebo in mean PBVC 46.7 37.3 . . .
T2 lesion volume 3300 mm3
No. of patientsb (c) 224 (174) 212 (172) 210 (160)
Mean (SD) −1.33 (1.45) −1.24 (1.54) −1.90 (1.74)
Median (range) −1.02 (−6.3 to 1.9) −1.05 (−13.5 to 2.0) −1.52 (−7.6 to 1.5)
P value vs placebod .003 .001 . . .
Percentage of relative reduction vs placebo in mean PBVC 29.9 34.5 . . .
Treatment naive
No. of patientsb (c) 259 (203) 244 (212) 249 (202)
Mean (SD) −0.84 (1.32) −0.90 (1.37) −1.19 (1.32)
Median (range) −0.66 (−5.6 to 2.0) −0.70 (−13.5 to 2.2) −1.01 (−6.5 to 2.4)
P value vs placebod .002 .02 . . .
Percentage of relative reduction vs placebo in mean PBVC 29.1 24.4 . . .
Previously treated
No. of patientsb (c) 170 (131) 181 (145) 169 (129)
Mean (SD) −0.95 (1.49) −0.76 (1.22) −1.49 (1.74)
Median (range) −0.73 (−6.3 to 3.0) −0.61 (−6.3 to 1.6) −0.97 (−7.6 to 1.5)
P value vs placebod .05 .002 . . .
Percentage of relative reduction vs placebo in mean PBVC 36.1 48.8 . . .
EDSS score 0-3.5
No. of patientsb (c) 351 (279) 363 (308) 346 (280)
Mean (SD) −0.79 (1.38) −0.79 (1.28) −1.18 (1.40)
Median (range) −0.57 (−6.3 to 3.0) −0.64 (−13.5 to 2.2) −0.89 (−7.6 to 2.4)
P value vs placebod .001 .001 . . .
Percentage of relative reduction vs placebo in mean PBVC 33.0 32.7 . . .
EDSS score 3.5
No. of patientsb (c) 78 (55) 62 (49) 72 (51)
Mean (SD) −1.37 (1.31) −1.16 (1.49) −2.00 (1.84)
Median (range) −0.94 (−4.2 to 1.3) −1.05 (−6.3 to 1.5) −1.51 (−7.0 to 1.3)
P value vs placebod .52 .10 . . .
Percentage of relative reduction vs placebo in mean PBVC 31.8 42.2 . . .
Abbreviations: EDSS, Expanded Disability Status Scale; ellipses, not applicable; PBVC, percentage of brain volume change.
aThere were no differences in the magnitude of the treatment effect of fingolimod between any of the subgroups of patients (eg, EDSS score 0-3.5 vs EDSS
score 3.5) as indicated by a lack of significance (P .10) in interaction for treatmentsubgroup.
bNumber of patients within subgroup in intent-to-treat population.
cNumber of patients within subgroup with nonmissing values from month 0 to month 24 (intent-to-treat population).
dRank analysis of covariance adjusted by treatment, baseline normalized brain volume, and geographic region (2-sided significance level of .05 within each
group).
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compared with only 21% of patients receiving placebo.
The rapid anti-inflammatory effect of fingolimod is cor-
roborated by a 6-month, placebo-controlled, phase 2 study
of fingolimod.29 In this phase 2 study, significant reduc-
tions in the number of Gd-enhancing lesions were de-
tected after only 2 months and at each monthly MRI up
to month 6 compared with placebo.
Importantly, the rate of brain volume loss over 2 years
was significantly reduced by fingolimod therapy vs pla-
cebo in the overall study population. This effect was evi-
dent by month 6 and was sustained during the remain-
der of the 2-year study. These data are consistent with
results of the companion 1-year Trial Assessing Inject-
able Interferon Versus FTY720 Oral in Relapsing-
Remitting Multiple Sclerosis (TRANSFORMS) study
comparing fingolimod with intramuscular interferon
beta-1a.30 In TRANSFORMS, fingolimod reduced brain
volume loss relative to intramuscular interferon beta-1a
during the controlled phase of the study, while patients
switching from intramuscular interferon beta-1a to fin-
golimod in the 1-year extension experienced marked slow-
ing of brain atrophy.31
In contrast to consistent benefits of fingolimod therapy
on brain atrophy observed in FREEDOMS and
TRANSFORMS, similar phase 3 studies of interferon beta
or natalizumab have shown an early acceleration of brain
volume loss (equal to or exceeding that of controls) dur-
ing the first year of treatment and a slowing during the
second year, but no significant difference over 2 years.17,21,22
For instance, in the AFFIRM study of natalizumab,24,30
brain volume loss over 2 years was similar in the natali-
zumab (–0.80%) and placebo (–0.82%) groups but dur-
ing the first year was greater with natalizumab (–0.56%)
than with placebo (–0.40%). The observed average rate
of brain volume loss in patients in the placebo and in-
tramuscular interferon beta-1a groups in FREEDOMS and
TRANSFORMS ranged from 0.40% to 0.56% during the
first year,7,11,15,32 values that are consistent with the na-
talizumab studies but at the lower end of those reported
previously for patients with relapsing-remitting MS (0.5%-
1.35% per year).18,33-36 This is consistent with a popula-
tion of patients that has shorter disease duration (10
years) and low disability (median EDSS score of 2.0) com-
pared with earlier studies or natural history cohorts.29
In the present study, the subgroup analyses revealed
more about the nature of the reductions in brain vol-
ume loss during fingolimod therapy. In patients with Gd-
enhancing lesions at baseline, the greater rate of brain
volume loss in year 1 than in year 2 in patients treated
with fingolimod may be consistent with the presence of
some degree of pseudoatrophy. In these individuals, the
anti-inflammatory effect of fingolimod results in fewer
lesions15,17 and reduced edema and may lead to initial loss
of brain volume compared with those without Gd-
enhancing lesions at baseline. The fact that this does not
lead to a greater rate of brain volume loss than in the pla-
cebo group, as seen with other MS therapies,17 may either
reflect a weaker anti-inflammatory effect24,29-31 or other
as yet unidentified mechanism independent of inflam-
mation. However, the rapid and significant reductions
in Gd-enhancing lesions indicate that fingolimod has po-
tent anti-inflammatory effects similar to other thera-
pies.17 Differences in the effect of disease-modifying thera-
pies on brain atrophy may be explained by differences
in mechanism of action, including the extent of anti-
inflammatory, neurodegenerative, and remyelinating ef-
fects in the central nervous system.33,37-39
The results of other subgroup analyses indicate that
fingolimod therapy is consistent across subgroups. Irre-
spective of baseline T2 lesion volume or previous treat-
ment status (the licensed 0.5-mg dose only), fingoli-
mod therapy significantly reduced brain volume loss over
2 years. The absence of a significant effect in patients with
EDSS scores more than 3.5 is probably due to the small
sample size in this group because the magnitude of the
reduction in brain volume loss was not substantially dif-
ferent from that in the much larger group of patients with
EDSS scores of 3.5 or less. The higher rates of brain vol-
ume loss across treatment groups observed in patients
with Gd-enhancing lesions or high T2 lesion volume
(3300 mm3) at baseline vs those without Gd-
enhancing lesions or low T2 lesion volume are consis-
tent with previous studies in individuals with relapsing
MS.15,16,19,33,38,39
Brain atrophy is widely recognized as a useful marker
for monitoring disease progression in MS.15,18 The clini-
cal relevance of therapeutically reduced brain volume loss
is underscored by the observations that atrophy is evi-
dent during the earliest stages of MS,7,18 proceeds relent-
lessly throughout the course of MS at higher rates than
in healthy individuals,15,19 and has a significant correla-
tion with physical disability.15,19 Furthermore, brain at-
rophy is considered to be a better MRI predictor of fu-
ture disability than T2 lesion load or T1 hypointense lesion
load.7,15,19 Therefore, the significant reduction in brain
atrophy over 2 years with fingolimod therapy comple-
ments the reported reductions in relapse rate and dis-
ability progression vs placebo.
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